July 27, 2017 / 8:24 PM / 2 years ago

BRIEF-Agile Therapeutics announces FDA acceptance of NDA resubmission of Twirla

July 27 (Reuters) - Agile Therapeutics Inc

* Agile Therapeutics announces FDA acceptance of the NDA resubmission of Twirla®

* Agile Therapeutics - FDA stated that it considers resubmission to be a complete response to CRL and established December 26, 2017 as PDUFA goal date

* U.S. Food and Drug Administration has accepted for review company’s new drug application resubmission for Twirla Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below